| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | FCRL3 |
| Uniprot No | Q96P31 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 18-573aa |
| 氨基酸序列 | GVAPKAVLLLNPPWSTAFKGEKVALICSSISHSLAQGDTYWYHDEKLLKIKHDKIQITEPGNYQCKTRGSSLSDAVHVEFSPDWLILQALHPVFEGDNVILRCQGKDNKNTHQKVYYKDGKQLPNSYNLEKITVNSVSRDNSKYHCTAYRKFYILDIEVTSKPLNIQVQELFLHPVLRASSSTPIEGSPMTLTCETQLSPQRPDVQLQFSLFRDSQTLGLGWSRSPRLQIPAMWTEDSGSYWCEVETVTHSIKKRSLRSQIRVQRVPVSNVNLEIRPTGGQLIEGENMVLICSVAQGSGTVTFSWHKEGRVRSLGRKTQRSLLAELHVLTVKESDAGRYYCAADNVHSPILSTWIRVTVRIPVSHPVLTFRAPRAHTVVGDLLELHCESLRGSPPILYRFYHEDVTLGNSSAPSGGGASFNLSLTAEHSGNYSCDADNGLGAQHSHGVSLRVTVPVSRPVLTLRAPGAQAVVGDLLELHCESLRGSFPILYWFYHEDDTLGNISAHSGGGASFNLSLTTEHSGNYSCEADNGLGAQHSKVVTLNVTGTSRNRTGLT |
| 预测分子量 | 67.4 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于FCRL3重组蛋白的3篇代表性文献的示例(注：以下内容为模拟示例，实际文献需通过学术数据库查询)：
1. **文献名称**：*"Structural and functional characterization of FCRL3 as a regulator of B-cell signaling"*
**作者**：Davis RS, et al.
**摘要**：研究解析了重组FCRL3蛋白的晶体结构，发现其胞外域具有独特的Ig样结构域，并通过体外实验证明FCRL3通过抑制BCR信号通路负向调控B细胞活化。
2. **文献名称**：*"FCRL3 polymorphisms and soluble recombinant FCRL3 protein in autoimmune thyroid disease"*
**作者**：Chu X, et al.
**摘要**：通过表达重组FCRL3蛋白并分析其与自身抗体的相互作用，发现FCRL3的特定变异体可能通过改变与IgG的结合能力，参与Graves病和桥本甲状腺炎的发病机制。
3. **文献名称**：*"Recombinant FCRL3 modulates TLR9 signaling in human dendritic cells"*
**作者**：Li FJ, et al.
**摘要**：利用重组FCRL3蛋白处理人树突状细胞，发现其通过抑制TLR9介导的NF-κB通路降低炎症因子分泌，提示其在免疫耐受中的潜在治疗作用。
如需具体文献，建议在PubMed或Google Scholar中搜索关键词“FCRL3 recombinant protein”获取最新研究。
Fc receptor-like 3 (FCRL3) is a transmembrane glycoprotein belonging to the Fc receptor-like (FCRL) family, which shares structural homology with classical Fc receptors but lacks direct Fc-binding capacity. Primarily expressed in immune cells—particularly B lymphocytes, regulatory T cells, and natural killer (NK) cells—FCRL3 plays a regulatory role in immune signaling. Its extracellular region contains immunoglobulin-like domains, while the intracellular domain features immunoreceptor tyrosine-based inhibitory motifs (ITIMs) and immunoreceptor tyrosine-based activation motifs (ITAMs), enabling dual signaling functions. FCRL3 modulates B cell receptor (BCR) signaling, influencing cell proliferation, apoptosis, and antibody production, and interacts with other immune checkpoints to balance immune activation and tolerance.
Genetic studies have linked FCRL3 polymorphisms, notably the -169T>C promoter variant (rs7528684), to susceptibility to autoimmune disorders, including rheumatoid arthritis, systemic lupus erythematosus, and autoimmune thyroid diseases. This SNP alters NF-κB binding affinity, potentially dysregulating FCRL3 expression and contributing to autoimmunity. Additionally, FCRL3 overexpression has been observed in certain B cell malignancies, suggesting a role in oncogenesis.
Recombinant FCRL3 protein, produced via expression systems like mammalian cells or Escherichia coli, retains functional domains for structural and interaction studies. It is widely used to investigate ligand-receptor interactions, immune pathway modulation, and therapeutic antibody development. Researchers employ it in ELISA, flow cytometry, and surface plasmon resonance (SPR) assays to study binding kinetics with putative ligands or autoantibodies. Its applications extend to vaccine design and biomarker discovery, offering insights into immune dysregulation mechanisms and targeted treatment strategies for autoimmune and neoplastic diseases.
×
